Oncology

Endometrial Cancer

Expert Roundtables Podcast: Adjuvant Therapy for Endometrial Cancer

expert roundtables by Floortje J. Backes, MD; Richard T. Penson, MD, MRCP; Pamela T. Soliman, MD, MPH

Overview

<p>The adjuvant therapy landscape for intermediate- to high-risk endometrial cancer is continuing to evolve. Join expert panelists Floortje J. Backes, MD, Richard T. Penson, MD, MRCP, and Pamela T. Soliman, MD, MPH, as they discuss key considerations for adjuvant therapy for endometrial cancer, including histology, stage, molecular subtype, and measurable residual disease status.</p> <p> </p> <p><iframe title="Expert Perspectives® in Endometrial Cancer with Dr Penson" width="500" height="281" src="https://www.youtube.com/embed/fe9ZTVhnhAA?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></p>

References

Corr BR, Erickson BK, Barber EL, Fisher CM, Slomovitz B. Advances in the management of endometrial cancer. BMJ. 2025;388:e080978. doi:10.1136/bmj-2024-080978

Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159-2170. doi:10.1056/NEJMoa2302312

Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182(6):1506-1519. doi:10.1067/mob.2000.107335

Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380(24):2317-2326. doi:10.1056/NEJMoa1813181

Mirza MR, Chase DM, Slomovitz BM, et al; RUBY Investigators. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145-2158. doi:10.1056/NEJMoa2216334

RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer. 2023;33(1):109-117. doi:10.1136/ijgc-2022-004039

Van Gorp T, Cibula D, Lv W, et al; ENGOT-en11/GOG-3053/KEYNOTE-B21 Investigators. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024;35(11):968-980. doi:10.1016/j.annonc.2024.08.2242

Zouzoulas D, Tsolakidis D, Sofianou I, et al. Molecular classification of endometrial cancer: impact on adjuvant treatment planning. Cytojournal. 2024;21:47. doi:10.25259/Cytojournal_37_2024

Profile

Floortje J. Backes, MD

Professor
Division of Gynecologic Oncology
The Ohio State University
Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University Wexner Medical Center
Columbus, OH

Profile

Richard T. Penson, MD, MRCP

Associate Professor of Medicine
Harvard Medical School
Medical Gynecologic Oncologist
Massachusetts General Hospital
Institutional Review Board Chair
Dana-Farber/Partners Cancer Care
Boston, MA

Profile

Pamela T. Soliman, MD, MPH

Professor and Chair Ad Interim
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX